Natera, Inc.

Equities

NTRA

US6323071042

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-09-13 pm EDT Pre-market 08:11:14 am
126.51 USD +1.11% Intraday chart for Natera, Inc. 128.74 +1.76%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Natera, Inc. Announces New Data from the GALAXY Arm of the Ongoing Circulate-Japan Trial at the 2024 Congress of the European Society for Medical Oncology in Barcelona, Spain CI
Transcript : Natera, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 02:35 PM
Transcript : Natera, Inc. Presents at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024, Aug-14-2024 12:30 PM
Natera's H2 Guidance Leaves 'Ample Room' for Upside, Morgan Stanley Says MT
Wall Street gets PPI relief, eyes now on CPI Our Logo
Morgan Stanley Adjusts Natera's PT to $132 From $125, Keeps Overweight Rating MT
Analyst recommendations: Dell, Palo Alto Networks, Snowflake, Warner Bros, Stellantis... Our Logo
UBS Adjusts Price Target on Natera to $145 From $160, Maintains Buy Rating MT
UBS Cuts Price Target on Natera to $145 From $160, Maintains Buy Rating MT
Natera Q2 Loss Narrows, Revenue Jumps MT
Natera Guides For Full Year 2024 Revenue of $1.49-$1.52 Billion, vs CIQ Analyst Consensus of $1.43 Billion MT
Transcript : Natera, Inc., Q2 2024 Earnings Call, Aug 08, 2024
Earnings Flash (NTRA) NATERA Reports Q2 Revenue $413.4M, vs. Street Est of $342.5M MT
Natera, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Natera, Inc. Provides Earnings Guidance for the Year 2024 CI
Jerome Powell did it again Our Logo
Analyst recommendations: Alphabet, Nike, Nvidia, Tesla, Starbucks... Our Logo
Natera Launches Phase 2 Gastroesophageal Cancer Trial Using Signatera MT
Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer CI
Natera Adds New Feature to Prospera Heart Test to Improve Detection of Rejection in Transplant Patients MT
Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients CI
Transcript : Natera, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM
Jefferies Initiates Natera at Buy Rating With $142 Price Target MT
Transcript : Natera, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 10:40 AM
U.S. FDA advisers back approval for Guardant's cancer test RE
Chart Natera, Inc.
More charts
Logo Natera, Inc.
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Employees
3,288
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
126.51USD
Average target price
129.33USD
Spread / Average Target
+2.23%
Consensus
  1. Stock Market
  2. Equities
  3. NTRA Stock
  4. News Natera, Inc.
  5. Natera's H2 Guidance Leaves 'Ample Room' for Upside, Morgan Stanley Says
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW